Quantcast

Latest Clinical research Stories

2014-07-28 20:25:54

BOSTON, July 28, 2014 /PRNewswire/ -- Hays Companies of Boston is pleased to announce Melissa Tobler is one of four individuals to date to receive the Validation Institute's Advanced Certification on Critical Outcomes Report Analysis. Intel-GE Care Innovations(TM) launched the Validation Institute to "challenge the status quo of typical healthcare research design principles, with the goal of positively impacting how the industry establishes credibility over time, but also ultimately...

2014-07-28 12:27:54

Hardison's election represents ConvergeHEALTH's commitment to standards-based innovation NEW YORK, July 28, 2014 /PRNewswire/ -- David Hardison, Ph.D., vice president of health services for ConvergeHEALTH by Deloitte, has been elected chairman of the board for the Clinical Data Interchange Standards Consortium, a non-profit working to establish common protocols around the use of clinical research data, particularly as it relates to electronic health records....

2014-07-28 08:29:32

-- Next-generation HNO prodrug targeting severe heart failure was well tolerated and showed hemodynamic activity in a Phase I clinical trial -- CHAPEL HILL, N.C., July 28, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. The company has now initiated dosing of hospitalized...

2014-07-28 08:28:49

TORONTO, July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multi-center, open-label,...

2014-07-26 00:20:52

REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso(TM) (sufentanil sublingual tablet system). The Company is currently...

2014-07-25 23:01:49

The Firm is representing hundreds of women who allegedly suffered serious vaginal mesh complications due to products manufactured by American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc. New York, New York (PRWEB) July 25, 2014 As thousands of transvaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) move forward in U.S. courts, Bernstein Liebhard LLP notes that the Food & Drug Administration (FDA) has rejected a petition by the...

2014-07-25 12:25:15

COSTA MESA, Calif., July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO WCCT Global welcomes Peter Nieto as the new Vice President of Business Development. Peter has been in the pharmaceutical industry for over 30 years in a number of different business development positions with some of the largest CROs in the industry. These positions were primarily related to business development/sales management and marketing. The experience he has obtained over the past 30 years makes him a...

2014-07-25 08:25:54

SAN DIEGO, July 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014. That same day, Arena will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for...

2014-07-25 00:21:04

REDWOOD CITY, Calif., July 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today confirmed the PDUFA date for Zalviso remains July 27, 2014. The company recently learned that a rumor circulated online stating the Food and Drug Administration (FDA) had approved Zalviso. As of July 24, 2014 there has been...

2014-07-24 23:13:47

DZS Clinical Services announced today that SBI Pharmaceuticals, the leading expert in research, development, and manufacturing of 5-ALA, has entered into a preferred provider agreement with DZS to manage several clinical programs related to the development of 5-ALA. Bound Brook, NJ (PRWEB) July 24, 2014 As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion. "We are delighted to have a...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related